{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:18Z","timestamp":1787237298094,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.oooo.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:43:09Z","timestamp":1744285389000},"page":"e59-e63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-4492","authenticated-orcid":false,"given":"Annu","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-6264","authenticated-orcid":false,"given":"Joseph M.","family":"Huryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-0671","authenticated-orcid":false,"given":"Cherry L.","family":"Estilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4508-5186","authenticated-orcid":false,"given":"Azeez","family":"Farooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-7569","authenticated-orcid":false,"given":"SaeHee K.","family":"Yom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2025.04.001_bib0001","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws - 2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2025.04.001_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/froh.2022.866871","article-title":"Oral complications in cancer patients-medication-related osteonecrosis of the jaw (MRONJ)","volume":"3","author":"Migliorati","year":"2022","journal-title":"Front Oral Health."},{"key":"10.1016\/j.oooo.2025.04.001_bib0003","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coms.2015.06.003","article-title":"The frequency of medication-related osteonecrosis of the jaw and its associated risk factors","volume":"27","author":"Dodson","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.oooo.2025.04.001_bib0004","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","article-title":"Medication-related osteonecrosis of the jaw: an update on the Memorial Sloan Kettering Cancer Center experience and the role of premedication dental evaluation in prevention","volume":"125","author":"Owosho","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2025.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2025.04.001_bib0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.oooo.2016.06.019","article-title":"Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series","volume":"122","author":"Owosho","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2025.04.001_bib0007","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.oooo.2025.04.001_bib0008","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.joms.2013.06.188","article-title":"Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis","volume":"72","author":"Magremanne","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2025.04.001_bib0009","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2025.04.001_bib0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jos.2020.01.012","article-title":"Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): a multicenter retrospective analysis in Japan","volume":"25","author":"Morishita","year":"2020","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.oooo.2025.04.001_bib0011","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00198-021-06078-z","article-title":"Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis","volume":"32","author":"Dos Santos Ferreira","year":"2021","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.oooo.2025.04.001_bib0012","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.oooo.2025.04.001_bib0013","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1563\/aaid-joi-D-19-00040","article-title":"Treatment of medication-related osteonecrosis of the jaw around the dental implant with a once-weekly teriparatide: a case report and literature review","volume":"45","author":"Kim","year":"2019","journal-title":"J Oral Implantol"},{"key":"10.1016\/j.oooo.2025.04.001_bib0014","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"10.1016\/j.oooo.2025.04.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.oooo.2025.04.001_bib0016","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440325008508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440325008508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:54:53Z","timestamp":1753318493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440325008508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2212440325008508"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2025.04.001","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}